Publicaciones en colaboración con investigadores/as de Instituto de Investigación Sanitaria del Hospital Universitario La Paz (107)

2024

  1. An Exploratory Approach of Clinically Useful Biomarkers of Cvid by Logistic Regression

    Journal of Clinical Immunology, Vol. 44, Núm. 6

  2. Atezolizumab Combined with Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer with a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial

    Journal of Clinical Oncology

  3. Clinical practice guideline on the management of vestibular schwannoma

    Acta Otorrinolaringologica Espanola, Vol. 75, Núm. 2, pp. 108-128

  4. Epidemiological and clinical characterization of community, healthcare-associated and nosocomial colonization and infection due to carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in Spain

    Infection

  5. Incidence of Diabetes Mellitus and Associated Factors in the Era of Antiretroviral Drugs With a Low Metabolic Toxicity Profile

    Open Forum Infectious Diseases, Vol. 11, Núm. 4

  6. Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial

    Annals of Oncology, Vol. 35, Núm. 11, pp. 981-992

  7. Novel risk loci for COVID-19 hospitalization among admixed American populations

    eLife, Vol. 13

  8. Progression-free survival and safety at 3.5 years of follow-up: results from the randomized phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer–a plain language summary

    Future Oncology, Vol. 20, Núm. 22, pp. 1531-1544

  9. Retrospective study assessing the role of the androgen receptor in clear cell renal cell cancer patients treated with VEGFR inhibitors in monotherapy

    Clinical and Translational Oncology

  10. Serum biomarkers for liver fibrosis assessment

    Advances in Laboratory Medicine, Vol. 5, Núm. 2, pp. 115-130

  11. Sleep apnoea increases biomarkers of immune evasion, lymphangiogenesis and tumour cell aggressiveness in high-risk patients and those with established lung cancer

    ERJ Open Research, Vol. 10, Núm. 1

  12. Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria, Swiss AGO, BGOG, CEEGOG, GEICO, and SFOG regarding the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in epithelial ovarian cancer

    Bulletin du Cancer, Vol. 111, Núm. 3, pp. 277-284

  13. Ulnar Distribution Pattern May Be Predominant in Upper Extremity Lymphatic Malformations

    Indian Journal of Surgery, Vol. 86, Núm. 4, pp. 756-759

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. CD137 (4-1BB) requires physically associated cIAPs for signal transduction and antitumor effects

    Science advances, Vol. 9, Núm. 33, pp. eadf6692

  3. Clinical and molecular signature of survival and resistance to olaparib plus pegylated liposomal doxorubicin in platinum-resistant ovarian cancer: A stratified analysis from the phase II clinical trial ROLANDO, GEICO-1601

    International Journal of Gynecological Cancer, Vol. 33, Núm. 6, pp. 929-936

  4. Consensus document on palliative care in cardiorenal patients

    Frontiers in Cardiovascular Medicine, Vol. 10

  5. Controversies in the treatment of advanced ovarian cancer in the PARP inhibitors era: a Delphi consensus

    Journal of gynecologic oncology, Vol. 34, Núm. 5, pp. e57

  6. Correction to: New update to the guidelines on testing predictive biomarkers in non‑small‑cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology (Clinical and Translational Oncology, (2022), 25, 5, (1252-1267), 10.1007/s12094-022-03046-9)

    Clinical and Translational Oncology

  7. Corrigendum to “Differences between childhood- and adulthood-onset eosinophilic esophagitis: An analysis from the EoE connect registry” [Digestive and Liver Disease Volume 55, Issue 3, March 2023, Pages 350–359] (Digestive and Liver Disease (2023) 55(3) (350–359), (S1590865822007289), (10.1016/j.dld.2022.09.020))

    Digestive and Liver Disease